CI Canadian Convertible Bond ETF Common (CXF) Stock Price, News & Analysis

Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: C$10.13 to C$10.13
• 50-Day Range: C$9.73 to C$10.23
• 52-Week Range: C$9.56 to C$10.57
• Volume: 1,400 shs
• Average Volume: 4,705 shs
• Market Capitalization: C$51.21 million
• P/E Ratio: N/A
• Dividend Yield: 4.74%
• Price Target: N/A
• Consensus Rating: N/A

CXF Stock Analysis - Frequently Asked Questions

How have CXF shares performed this year?

CI Canadian Convertible Bond ETF Common's stock was trading at C$10.29 at the start of the year. Since then, CXF shares have decreased by 1.6% and is now trading at C$10.13.
View the best growth stocks for 2025 here.

How do I buy shares of CI Canadian Convertible Bond ETF Common?

Shares of CXF stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of CI Canadian Convertible Bond ETF Common own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CI Canadian Convertible Bond ETF Common investors own include Golden Minerals (AUMN), Tesla (TSLA), iA Financial (IAG), Northland Power (NPI), Allied Properties Real Estate Investment Trust (AP.UN), Capital Power (CPX) and Enerplus (ERF).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:CXF
• CIK: N/A
• Web: N/A
• Phone: (919) 806-1074
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,054,940
• Free Float: N/A
• Market Cap: C$51.21 million
• Optionable: Not Optionable
• Beta: N/A